The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, independent review of the 66th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2015). This program consists of six components: (1) CME Internet Symposium: AASLD 2015 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on AASLD 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in the EU; (3) CME Internet Symposium: Brazilian Perspective on AASLD 2015: a 1-hour Internet symposium featuring Brazil-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in Brazil; (4) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (5) Rapid-Fire Independent Review of AASLD 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (6) From Conference To Clinic: Reviewing And Applying Data From AASLD 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C therapy presented at AASLD 2015. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
All online components of the program will be accessible at www.viraled.com.This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2015 and it is not sanctioned by the organizers of AASLD 2015.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
After completing this activity, the participant should be better able to:
Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2015
Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at AASLD 2015, to improve patient care
Engage patients and colleagues in a discussion on studies and data presented at AASLD 2015 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC
Release Date: November 30, 2015
Expiration Date: November 30, 2016
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany
Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Mauro Schechter, MD, PhD
Professor of Infectious Diseases
Department of Preventive Medicine
Federal University of Rio de Janeiro, Brazil
Rio de Janeiro, Brazil
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.
Doug Dieterich, MD
Paul Kwo, MD
Paul Pockros, MD
Juergen Rockstroh, MD
Mauro Schechter, MD
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 |
High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6 infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study | |
 |
RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non Cirrhotic HCV Genotype 1-Infected Patients with Severe Renal Impairment or End-Stage Renal Disease | |
 |
C-EDGE CO-STAR: Efficacy of Grazoprevir and Elbasvir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy | |
 |
Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute Hepatitis C Virus Infection in HIV-1 infected Individuals (SWIFT-C) and Sofosbuvir and Ribavirin for Six Weeks Is Not Effective Among People with Acute and Recently Acquired HCV Infection: The DARE-C II Study | |
 |
Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network | |
 |
98%-100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null Responders with the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 (SURVEYOR-1) and High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment- Experienced Patients With HCV Genotype 3 Infection (SURVEYOR-2) |
|
 |
The ASTRAL Program | |
 |
All-Oral Treatment With Daclatasvir (DCV) Plus Sofosbuvir (SOF) Plus Ribavirin (RBV) for 12 or 16 Weeks in HCV Genotype (GT) 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study | |
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
on dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other
authorities.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2015 and it is not sanctioned by the organizers of AASLD 2015.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs and Merck & Co.
